世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market is poised for steady growth, supported by increasing cases of ophthalmic disorders and rising global geriatric pop... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market is poised for steady growth, supported by increasing cases of ophthalmic disorders and rising global geriatric population. According to newly updated industry analysis by Fairfield Market Research, the market is expected to grow from a valuation of US$ 12.3 Bn in 2025 to reach approximately US$ 13.3 Bn by 2032, reflecting a moderate compound annual growth rate (CAGR) of 1.09%.Market Insights Anti-VEGF therapeutics are a cornerstone in the treatment of various diseases associated with abnormal blood vessel growth, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. These therapeutics work by inhibiting the activity of VEGF proteins, which are responsible for promoting angiogenesis. Among the product types, Eylea continues to dominate the market, owing to its widespread clinical use and emerging drug delivery advancements. As of 2025, Eylea is anticipated to remain the top revenue-generating product, owing to rising adoption in treating vision-related complications. Age-related macular degeneration, a key disease area for anti-VEGF therapies, is witnessing growing incidence, particularly among aging populations worldwide. Market Drivers One of the primary drivers fueling market growth is the growing prevalence of diabetic macular edema and age-related macular degeneration, both of which are major contributors to global blindness. Anti-VEGF therapies, which are administered via intraocular injections, have proven more effective than traditional laser photocoagulation methods. As a result, these therapies are fast becoming the preferred treatment choice. In the oncology segment, anti-VEGF therapeutics are gaining momentum due to their ability to inhibit tumor angiogenesis. Since many tumors show overexpression of VEGF proteins, targeted therapies using monoclonal antibodies such as bevacizumab have emerged as a significant treatment route. With cancer incidence projected to rise significantly over the coming years, the role of anti-VEGF drugs in cancer management is expected to grow. Business Opportunity Despite relatively modest CAGR projections, the anti-VEGF therapeutics market continues to present strong opportunities in both developed and emerging economies. Increased investment in research and development, regulatory support, and growing awareness about early diagnosis of eye disorders provide an optimistic outlook. Additionally, the expansion of drug delivery technologies, such as pre-filled syringes and port delivery systems, are anticipated to enhance patient compliance and treatment effectiveness. The aging population will remain a key growth enabler. By 2050, the global population aged 60 years and above is projected to surpass 2 billion. This demographic shift is expected to substantially increase the prevalence of retinal disorders, thereby boosting demand for anti-VEGF therapies. Regional Analysis North America is projected to maintain its leading position in the global anti-VEGF therapeutics market through 2032. The region benefits from a large geriatric population, favorable reimbursement policies, and strong healthcare infrastructure. Moreover, U.S.-based companies continue to drive innovations and product approvals, making the country a lucrative hub for market growth. In Europe and Asia Pacific, increased healthcare spending, awareness programs, and adoption of advanced ophthalmic treatments are contributing to growth. Japan and the U.K., in particular, are witnessing rising demand due to their aging populations and well-established pharmaceutical industries. Key Players The competitive Analysis of the anti-VEGF therapeutics market includes several leading pharmaceutical companies actively focusing on research, product launches, and regulatory approvals. Major market participants include: • F. Hoffmann-La Roche Ltd. • Biogen • Pfizer Inc. • Coherus BioSciences • Amgen Inc. • Regeneron Pharmaceuticals Inc. • Bayer AG • Novartis AG These companies are continually working on novel formulations and combination therapies to address unmet clinical needs and improve patient outcomes. Notably, Regeneron and Roche have been at the forefront of launching innovative delivery systems and expanding indications for their leading products. Segmentation By Product Type: • Eylea • Lucentis • Beovu By Disease Type: • Macular Edema • Diabetic Retinopathy • Retinal Vein Occlusion • Age-related Macular Degeneration By Region: • North America • Latin America • Europe • Asia Pacific • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2019-2032 3.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Eylea 3.1.1.2. Lucentis 3.1.1.3. Beovu 3.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Macular Edema 3.2.1.2. Diabetic Retinopathy 3.2.1.3. Retinal Vein Occlusion 3.2.1.4. Age-related Macular Degeneration 3.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Region, Value (US$ Bn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2019-2032 4.1. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Eylea 4.1.1.2. Lucentis 4.1.1.3. Beovu 4.2. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Macular Edema 4.2.1.2. Diabetic Retinopathy 4.2.1.3. Retinal Vein Occlusion 4.2.1.4. Age-related Macular Degeneration 4.2.2. BPS Analysis/Market Attractiveness Analysis 4.3. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 4.3.1.2. U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 4.3.1.3. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 4.3.1.4. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2019-2032 5.1. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Eylea 5.1.1.2. Lucentis 5.1.1.3. Beovu 5.2. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Macular Edema 5.2.1.2. Diabetic Retinopathy 5.2.1.3. Retinal Vein Occlusion 5.2.1.4. Age-related Macular Degeneration 5.2.2. BPS Analysis/Market Attractiveness Analysis 5.3. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.2. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.1.3. U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.4. U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.1.5. France Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.6. France Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.1.7. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.8. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.1.9. Turkey Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.10. Turkey Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.1.11. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.12. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.1.13. Rest of Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 5.3.1.14. Rest of Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2019-2032 6.1. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Eylea 6.1.1.2. Lucentis 6.1.1.3. Beovu 6.2. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Macular Edema 6.2.1.2. Diabetic Retinopathy 6.2.1.3. Retinal Vein Occlusion 6.2.1.4. Age-related Macular Degeneration 6.2.2. Others BPS Analysis/Market Attractiveness Analysis 6.3. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 6.3.1.2. China Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 6.3.1.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 6.3.1.4. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 6.3.1.5. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 6.3.1.6. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 6.3.1.7. India Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 6.3.1.8. India Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 6.3.1.9. Southeast Asia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 6.3.1.10. Southeast Asia Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 6.3.1.11. Rest of Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 6.3.1.12. Rest of Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2019-2032 7.1. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Eylea 7.1.1.2. Lucentis 7.1.1.3. Beovu 7.2. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032 7.2.1.1. Macular Edema 7.2.1.2. Diabetic Retinopathy 7.2.1.3. Retinal Vein Occlusion 7.2.1.4. Age-related Macular Degeneration 7.2.2. BPS Analysis/Market Attractiveness Analysis 7.3. Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 7.3.1.2. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 7.3.1.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 7.3.1.4. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 7.3.1.5. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 7.3.1.6. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 7.3.1.7. Rest of Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 7.3.1.8. Rest of Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, 2019-2032 8.1. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Eylea 8.1.1.2. Lucentis 8.1.1.3. Beovu 8.2. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Macular Edema 8.2.1.2. Diabetic Retinopathy 8.2.1.3. Retinal Vein Occlusion 8.2.1.4. Age-related Macular Degeneration 8.2.2. BPS Analysis/Market Attractiveness Analysis 8.3. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook, by Country, Value (US$ Bn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. GCC Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 8.3.1.2. GCC Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 8.3.1.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 8.3.1.4. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 8.3.1.5. Egypt Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 8.3.1.6. Egypt Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 8.3.1.7. Nigeria Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 8.3.1.8. Nigeria Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 8.3.1.9. Rest of Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type, Value (US$ Bn), 2019-2032 8.3.1.10. Rest of Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Type, Value (US$ Bn), 2019-2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Manufacturer vs by Disease Type Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. F. Hoffmann-La Roche Ltd. 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Development 9.4.2. Biogen 9.4.2.1. Company Overview 9.4.2.2. Product Portfolio 9.4.2.3. Financial Overview 9.4.2.4. Business Strategies and Development 9.4.3. Pfizer Inc 9.4.3.1. Company Overview 9.4.3.2. Product Portfolio 9.4.3.3. Financial Overview 9.4.3.4. Business Strategies and Development 9.4.4. CoherusBioSciences 9.4.4.1. Company Overview 9.4.4.2. Product Portfolio 9.4.4.3. Financial Overview 9.4.4.4. Business Strategies and Development 9.4.5. Amgen Inc 9.4.5.1. Company Overview 9.4.5.2. Product Portfolio 9.4.5.3. Financial Overview 9.4.5.4. Business Strategies and Development 9.4.6. Regeneron Pharmaceuticals Inc. 9.4.6.1. Company Overview 9.4.6.2. Product Portfolio 9.4.6.3. Financial Overview 9.4.6.4. Business Strategies and Development 9.4.7. Bayer AG 9.4.7.1. Company Overview 9.4.7.2. Product Portfolio 9.4.7.3. Financial Overview 9.4.7.4. Business Strategies and Development 9.4.8. Novartis AG 9.4.8.1. Company Overview 9.4.8.2. Product Portfolio 9.4.8.3. Financial Overview 9.4.8.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（therapeutics）の最新刊レポートよくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
